ARM001(ARM001) - 在研适应症：血液肿瘤_专利_临床

概要

基本信息

药物类型

细胞疗法

别名

靶点-

作用机制-

治疗领域

肿瘤血液及淋巴系统疾病

在研适应症

血液肿瘤

非在研适应症-

原研机构

星尘生物科技（上海）有限公司初创企业

在研机构

星尘生物科技（上海）有限公司初创企业

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)早期临床1期

特殊审评-

登录后查看时间轴

关联

100 项与 ARM001 相关的临床结果

登录后查看更多信息

100 项与 ARM001 相关的转化医学

登录后查看更多信息

100 项与 ARM001 相关的专利（医药）

登录后查看更多信息

1

项与 ARM001 相关的文献（医药）

2024-01-23·NAR Molecular Medicine

A small molecule that inhibits the evolution of antibiotic resistance

Article

作者: Kim, Kwangho ; Egli, Martin ; Merrikh, Houra ; Carvajal-Garcia, Juan ; Hernandez Viera, Angel J ; Jaremba, Emily A ; Bracey, Harrison ; Simsek, Esra N ; Johnson, Anna E

AbstractAntibiotic resistance rapidly develops against almost all available therapeutics. Therefore, searching for new antibiotics to overcome the problem of antibiotic resistance alone is insufficient. Given that antibiotic resistance can be driven by mutagenesis, an avenue for preventing it is the inhibition of mutagenic processes. We previously showed that the DNA translocase Mfd is mutagenic and accelerates antibiotic resistance development. Here, we present our discovery of a small molecule that inhibits Mfd-dependent mutagenesis, ARM-1 (anti-resistance molecule 1). We found ARM-1 using a high-throughput, small molecule, in vivo screen. Using biochemical assays, we characterized the mechanism by which ARM-1 inhibits Mfd. Critically, we found that ARM-1 reduces mutagenesis and significantly delays antibiotic resistance development across highly divergent bacterial pathogens. These results demonstrate that the mutagenic proteins accelerating evolution can be directly inhibited. Furthermore, our findings suggest that Mfd inhibition, alongside antibiotics, is a potentially effective approach for prevention of antibiotic resistance development during treatment of infections.

100 项与 ARM001 相关的药物交易

登录后查看更多信息